From the Journals

Improved adenoma detection rate found protective against interval cancers, death

View on the News

ADR improvement is possible

The U.S. Multi-Society Task Force on Colorectal Cancer proposed the adenoma detection rate (ADR) as a colonoscopy quality measure in 2002. The rationale for a new measure was emerging evidence of highly variable adenoma detection and cancer prevention among colonoscopists. Highly variable performance, consistently verified in subsequent studies, casts a pall of severe operator dependence over colonoscopy. In landmark studies from Kaminski et al. and Corley et al. in 2010 and 2014, respectively, it was shown that doctors with higher ADRs provide patients with much greater protection against interval colorectal cancer (CRC).

Dr. Douglas Rex

A huge body of work investigated whether colonoscopists can improve ADRs. After initial setbacks, methods of ADR improvement have been convincingly demonstrated.

Now Kaminski and colleagues from Poland have delivered a second landmark study, demonstrating for the first time that improving ADR prevents CRCs. We now have strong evidence that ADR predicts the level of cancer prevention, that ADR improvement is achievable, and that improving ADR further prevents CRCs and CRC deaths. Thanks to this study, ADR has come full circle. Measurement of and improvement in detection is now a fully validated concept that is essential to modern colonoscopy. In 2017, ADR measurement is mandatory for all practicing colonoscopists who are serious about CRC prevention. The tools to improve ADR that are widely accepted include ADR measurement and reporting, split or same-day preparations, lesion recognition and optimal technique, high-definition imaging, double examination (particularly for the right colon), patient rotation during withdrawal, chromoendoscopy, mucosal exposure devices (caps, cuffs, balloons, etc.), and water exchange. Tools for ADR improvement that are emerging or under study are brighter forms of electronic chromoendoscopy, and videorecording.

Douglas K. Rex, MD, is professor of medicine, division of gastroenterology/hepatology, at Indiana University, Indianapolis.* He has no relevant conflicts of interest.

Correction, 6/20/17: An earlier version of this article misstated Dr. Rex's affiliation.


 

FROM GASTROENTEROLOGY

An improved annual adenoma detection rate was associated with a significantly decreased risk of interval colorectal cancer (ICRC) and subsequent death in a national prospective cohort study published in the July issue of Gastroenterology (doi: 10.1053/j.gastro.2017.04.006).

Source: American Gastroenterological Association

This is the first study to show a significant inverse relationship between an improved annual adenoma detection rate (ADR) and ICRC or subsequent death, Michal F. Kaminski MD, PhD, of the Institute of Oncology, Warsaw, wrote with his associates.

The rates of these outcomes were lowest when endoscopists achieved and maintained ADRs above 24.6%, which supports the currently recommended performance target of 25% for a mixed male-female population, they reported (Am J Gastroenterol. 2015;110:72-90).

colonoscopy Eraxion/Thinkstock
This study included 294 endoscopists and 146,860 individuals who underwent screening colonoscopy as part of a national cancer prevention program in Poland between 2004 and 2008. Endoscopists received annual feedback based on quality benchmarks to spur improvements in colonoscopy performance, and all participated for at least 2 years. For each endoscopist, investigators categorized annual ADRs based on quintiles for the entire data set. “Improved ADR” was defined as keeping annual ADR within the highest quintile (above 24.6%) or as increasing annual ADR by at least one quintile, compared with baseline.

Based on this definition, 219 endoscopists (75%) improved their ADR during a median of 5.8 years of follow-up (interquartile range, 5-7.2 years). In all, 168 interval CRCs were diagnosed, of which 44 cases led to death. After age, sex, and family history of colorectal cancer were controlled for, patients whose endoscopists improved their ADRs were significantly less likely to develop (adjusted hazard ratio, 0.6; 95% confidence interval, 0.5-0.9; P = .006) or to die of interval CRC (95% CI, 0.3-0.95; P = .04) than were patients whose endoscopists did not improve their ADRs.

Maintaining ADR in the highest quintile (above 24.6%) throughout follow-up led to an even lower risk of interval CRC (HR, 0.3; 95% CI, 0.1-0.6; P = .003) and death (HR, 0.2; 95% CI, 0.1-0.6; P = .003), the researchers reported. In absolute numbers, that translated to a decrease from 25.3 interval CRCs per 100,000 person-years of follow-up to 7.1 cases when endoscopists eventually reached the highest ADR quintile or to 4.5 cases when they were in the highest quintile throughout follow-up. Rates of colonic perforation remained stable even though most endoscopists upped their ADRs.

Together, these findings “prove the causal relationship between endoscopists’ ADRs and the likelihood of being diagnosed with, or dying from, interval CRC,” the investigators concluded. The national cancer registry in Poland is thought to miss about 10% of cases, but the rate of missing cases was not thought to change over time, they noted. However, they also lacked data on colonoscope withdrawal times, and had no control group to definitively show that feedback based on benchmarking was responsible for improved ADRs.

Funders included the Foundation of Polish Science, the Innovative Economy Operational Programme, the Polish Foundation of Gastroenterology, the Polish Ministry of Health, and the Polish Ministry of Science and Higher Education. The investigators reported having no relevant conflicts of interest.

Recommended Reading

Elderly black individuals at higher risk of colorectal cancer
MDedge Hematology and Oncology
Oral HPV infections sharply lower for vaccinated youth
MDedge Hematology and Oncology
FDA okays pembrolizumab for certain solid tumors with common biomarker
MDedge Hematology and Oncology
Five year survival doubles for younger women with de novo MBC
MDedge Hematology and Oncology
Breast cancer liquid biopsies don’t change outcomes....yet
MDedge Hematology and Oncology
As government-funded cancer research sags, scientists fear U.S. is ‘losing its edge’
MDedge Hematology and Oncology
VIDEO: Childhood cancer survivors living longer with fewer severe health problems
MDedge Hematology and Oncology
VIDEO: Low testosterone common after testicular cancer
MDedge Hematology and Oncology
Severe health conditions decline in childhood cancer survivors
MDedge Hematology and Oncology
Lung cancer linked to suicide
MDedge Hematology and Oncology